Home > Dermatology > AAD 2020 > IL-17A and IL-17F blockade remarkably effective in psoriasis

IL-17A and IL-17F blockade remarkably effective in psoriasis

The two phase 3 trials BE VIVID and BE READY showed that the IL-17A and IL-17F blocker bimekizumab is remarkably effective in moderate-to-severe psoriasis [1,2]. In the BE READY trial, bimekizumab showed a durable effect with only 1 injection every 8 weeks [2].

The IL-17 family of cytokines is important in the regulation of both innate and adaptive host defences and inflammation. Not only IL-17A but also IL-17F is expressed in psoriasis lesional skin and amplifies tissue damage and inflammation. Bimekizumab neutralises the biologic function of both IL-17F and IL-17A, which might have more benefits than the sole blockade of IL-17A. “We have interesting data to suggest that IL-17F contributes to the psoriasis disease process, so hopefully with this drug we will see a higher response,” said Prof. Reich (University Medical Center Hamburg-...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on